38
Participants
Start Date
June 15, 2017
Primary Completion Date
March 31, 2018
Study Completion Date
June 12, 2018
ABI-H0731
A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
Placebo for ABI-H0731
Sugar pill manufactured to mimic the ABI-H0731 tablet
Entecavir
An antiviral medication used in the treatment of hepatitis B virus infection
Tenofovir Disoproxil Fumarate
An antiviral medication used in the treatment of hepatitis B virus infection
Pegasys
Used to treat adults with chronic hepatitis B virus who show signs of liver damage
Monash University, Clayton
St. Vincent's Hospital, Fitzroy
The Alfred Hospital, Melbourne
Linear Clinical Research, Nedlands
University of Hong Kong, Hong Kong
Hallym University, Chuncheon
CHA Bundang Medical Center, Gyeonggi-do
Asan Medical Center, Seoul
Severance Hospital, Yonsei University, Seoul
Keelung Chang Gung Memorial Hospital, Keelung
National Taiwan University Hospital, Taipei
King's College Hospital, London
Royal Free Hospital NHS Foundation Trust, London
Royal London Hospital, London
Lead Sponsor
Assembly Biosciences
INDUSTRY